{
    "2020-05-17": [
        [
            {
                "time": "",
                "original_text": "恒瑞、科伦、中国生物制药？谁会成为注射剂一致性评价的赢家？",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "科伦",
                        "中国生物制药",
                        "注射剂",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "重销售轻研发，警惕这些畸形发展的药企",
                "features": {
                    "keywords": [
                        "销售",
                        "研发",
                        "畸形发展",
                        "药企"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-05",
                "original_text": "【国信医药】继续紧握龙头，重视IVD需求弹性（5月投资策略）",
                "features": {
                    "keywords": [
                        "国信医药",
                        "龙头",
                        "IVD",
                        "需求弹性",
                        "投资策略"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "IVD"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "巨丰原创：后疫情时代 低估值医药股受资金关注 两主线可以加码",
                "features": {
                    "keywords": [
                        "后疫情时代",
                        "低估值",
                        "医药股",
                        "资金关注",
                        "两主线",
                        "加码"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}